Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

This study tests THEO-260, a new drug delivered directly into the abdominal cavity (intraperitoneally), for women with advanced ovarian, fallopian tube, or peritoneal cancer whose cancer has stopped responding to platinum-based chemotherapy. **You may be eligible if...** - You have advanced high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer confirmed by biopsy - Your cancer has progressed during or within 6 months of platinum chemotherapy (platinum-resistant or refractory) - Your life expectancy is more than 6 months - Your blood counts and organ function meet required thresholds - You are not pregnant or breastfeeding, and you are post-menopausal or using effective contraception **You may NOT be eligible if...** - Your cancer is not platinum-resistant or refractory - You have had too many prior lines of treatment (as determined by the study team) - Your organ function is significantly impaired Talk to your doctor to see if this trial is right for you.